{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:20:34Z","timestamp":1759339234243},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T00:00:00Z","timestamp":1435881600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12883-015-0353-x","type":"journal-article","created":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T20:20:52Z","timestamp":1435782052000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine"],"prefix":"10.1186","volume":"15","author":[{"given":"Andrew M.","family":"Blumenfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheena K.","family":"Aurora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Laranjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros","family":"Papapetropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,3]]},"reference":[{"key":"353_CR1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","volume":"30","author":"J Natoli","year":"2010","unstructured":"Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599\u2013609.","journal-title":"Cephalalgia"},{"key":"353_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413487610","volume":"33","author":"J Olesen","year":"2013","unstructured":"Olesen J. Headache Classification Committee of the International Headache Society (IHS): The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629\u2013808.","journal-title":"Cephalalgia"},{"key":"353_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559\u201366.","journal-title":"Neurology"},{"key":"353_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1526-4610.2009.01369.x","volume":"49","author":"J Munakata","year":"2009","unstructured":"Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2009;49:498\u2013508.","journal-title":"Headache"},{"key":"353_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"A Blumenfeld","year":"2011","unstructured":"Blumenfeld A, Varon S, Wilcox TK, Buse D, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301\u201315.","journal-title":"Cephalalgia"},{"key":"353_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/JOM.0b013e3181c1dc56","volume":"52","author":"WF Stewart","year":"2010","unstructured":"Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and Work Impact of Chronic Migraine and Episodic Migraine. J Occup Environ Med. 2010;52:8\u201314.","journal-title":"J Occup Environ Med"},{"key":"353_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"353_CR8","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1046\/j.1468-2982.2002.00426.x","volume":"22","author":"MF Peres","year":"2002","unstructured":"Peres MF, Zukerman E, Young WB, Silberstein SD. Fatigue in chronic migraine patients. Cephalalgia. 2002;22:720\u20134.","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"353_CR9","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","volume":"43","author":"KR Aoki","year":"2003","unstructured":"Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43 Suppl 1:S9\u201315.","journal-title":"Headache"},{"key":"353_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785\u201393.","journal-title":"Neurotoxicology"},{"key":"353_CR11","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1111\/j.1526-4610.2006.00675.x","volume":"47","author":"R Hargreaves","year":"2007","unstructured":"Hargreaves R. New migraine and pain research. Headache. 2007;47:S26\u201343.","journal-title":"Headache"},{"issue":"Suppl 1","key":"353_CR12","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.parkreldis.2011.06.013","volume":"17","author":"KR Aoki","year":"2011","unstructured":"Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord. 2011;17 Suppl 1:S28\u201333.","journal-title":"Parkinsonism Relat Disord"},{"key":"353_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse R, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921\u201336.","journal-title":"Headache"},{"key":"353_CR14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","volume":"28","author":"S Silberstein","year":"2008","unstructured":"Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28:484\u201395.","journal-title":"Cephalalgia"},{"key":"353_CR15","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092\u20137.","journal-title":"Arch Intern Med"},{"key":"353_CR16","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/WNL.53.5.988","volume":"53","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999;53:988\u201394.","journal-title":"Neurology"},{"key":"353_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606\u201313.","journal-title":"J Gen Intern Med"},{"key":"353_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193\u2013213.","journal-title":"Psychiatry Res"},{"key":"353_CR19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121\u20133.","journal-title":"Arch Neurol"},{"key":"353_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0304-3959(00)00380-8","volume":"89","author":"SJ Wang","year":"2001","unstructured":"Wang SJ, Fuh JL, Lu SR, Juang KD. Quality of life differs among headache diagnoses: analysis of SF-36 survey in 901 headache patients. Pain. 2001;89:285\u201392.","journal-title":"Pain"},{"key":"353_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","volume":"38","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1998;38:295\u2013302.","journal-title":"Headache"},{"key":"353_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jama.2010.1937","volume":"305","author":"A Albanese","year":"2011","unstructured":"Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA. 2011;305:89\u201390.","journal-title":"JAMA"},{"key":"353_CR23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1526-4610.2002.02122.x","volume":"42","author":"JR Saper","year":"2002","unstructured":"Saper JR, Lake III AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470\u201382.","journal-title":"Headache"},{"key":"353_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1526-4610.1994.hed3409497.x","volume":"34","author":"JR Saper","year":"1994","unstructured":"Saper JR, Silberstein SD, Lake III AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994;34:497\u2013502.","journal-title":"Headache"},{"key":"353_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10194-008-0002-5","volume":"9","author":"VA Yurekli","year":"2008","unstructured":"Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9:37\u201341.","journal-title":"J Headache Pain"},{"key":"353_CR26","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1212\/01.WNL.0000100121.58594.11","volume":"61","author":"PJ Spira","year":"2003","unstructured":"Spira PJ, Beran RG. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61:1753\u20139.","journal-title":"Neurology"},{"key":"353_CR27","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1046\/j.1468-2982.2003.00592.x","volume":"23","author":"M Silvestrini","year":"2003","unstructured":"Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23:820\u20134.","journal-title":"Cephalalgia"},{"key":"353_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","volume":"47","author":"SD Silberstein","year":"2007","unstructured":"Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170\u201380.","journal-title":"Headache"},{"key":"353_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse R, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804\u201314.","journal-title":"Cephalalgia"},{"key":"353_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse R, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793\u2013803.","journal-title":"Cephalalgia"},{"key":"353_CR31","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","volume":"51","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse R, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358\u201373.","journal-title":"Headache"},{"key":"353_CR32","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","volume":"50","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406\u201318.","journal-title":"Headache"},{"key":"353_CR33","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware Jr JE, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12:963\u201374.","journal-title":"Qual Life Res"},{"key":"353_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1046\/j.1526-4610.2003.03050.x","volume":"43","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Lipton RB, Kolodner K. Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache. 2003;43:258\u201365.","journal-title":"Headache"},{"key":"353_CR35","first-page":"1","volume":"32","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL. The PHQ-9: A new depression diagnostic and severity measure. Psych Ann. 2002;32:1\u20137.","journal-title":"Psych Ann"},{"key":"353_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/01.wnf.0000192136.46145.44","volume":"28","author":"M Bartolini","year":"2005","unstructured":"Bartolini M, Silvestrini M, Taffi R, Lanciotti C, Luconi R, Capecci M, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol. 2005;28:277\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"353_CR37","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"HC Diener","year":"2007","unstructured":"Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814\u201323.","journal-title":"Cephalalgia"},{"key":"353_CR38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1046\/j.1526-4610.2002.02125.x","volume":"42","author":"AV Krymchantowski","year":"2002","unstructured":"Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002;42:510\u20134.","journal-title":"Headache"},{"key":"353_CR39","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","volume":"49","author":"NT Mathew","year":"2009","unstructured":"Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxinA (BOTOX\u00ae) and topiramate (TOPAMAX\u00ae) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;49:1466\u201378.","journal-title":"Headache"},{"key":"353_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","volume":"51","author":"RK Cady","year":"2011","unstructured":"Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A Multi-Center Double-Blind Pilot Comparison of OnabotulinumtoxinA and Topiramate for the Prophylactic Treatment of Chronic Migraine. Headache. 2011;51:21\u201332.","journal-title":"Headache"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-015-0353-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0353-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0353-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0353-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T07:44:22Z","timestamp":1551167062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-015-0353-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,3]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["353"],"URL":"https:\/\/doi.org\/10.1186\/s12883-015-0353-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,3]]},"assertion":[{"value":"15 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"100"}}